Published in J Am Coll Cardiol on March 19, 2003
Aspirin Non-responsiveness and Clopidogrel Endpoint Trial. (ASCET) | NCT00222261
Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation (2012) 2.76
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest (2003) 1.90
A novel variant in the platelet endothelial aggregation receptor-1 gene is associated with increased platelet aggregability. Arterioscler Thromb Vasc Biol (2008) 1.29
Resistance to aspirin is increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels. Thromb J (2005) 1.15
Identification of a specific intronic PEAR1 gene variant associated with greater platelet aggregability and protein expression. Blood (2011) 1.13
Platelet hyperreactivity: predictive and intrinsic properties. Hematol Oncol Clin North Am (2007) 1.06
Thrombosis and antithrombotic therapy in women. Arterioscler Thromb Vasc Biol (2009) 1.03
Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood (2006) 1.03
Cardiovascular pharmacogenomics. Circ Res (2011) 1.03
Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements. Nat Rev Cardiol (2009) 0.97
Microfluidic thrombosis under multiple shear rates and antiplatelet therapy doses. PLoS One (2014) 0.95
Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients. J Transl Med (2008) 0.95
Antiplatelet drug 'resistance'. Part 2: laboratory resistance to antiplatelet drugs-fact or artifact? Nat Rev Cardiol (2009) 0.94
Aspirin resistance: a new independent predictor of vascular events? J Am Coll Cardiol (2003) 0.93
Aspirin and clopidogrel resistance: methodological challenges and opportunities. Vasc Health Risk Manag (2010) 0.93
Suboptimal inhibition of platelet cyclooxygenase-1 by aspirin in metabolic syndrome. Hypertension (2012) 0.92
Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting. Vasc Health Risk Manag (2009) 0.90
Pharmacometabolomics reveals that serotonin is implicated in aspirin response variability. CPT Pharmacometrics Syst Pharmacol (2014) 0.90
High On-Aspirin Platelet Reactivity and Clinical Outcome in Patients With Stable Coronary Artery Disease: Results From ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial). J Am Heart Assoc (2012) 0.89
The PlA1/A2 polymorphism of glycoprotein IIIa in relation to efficacy of antiplatelet drugs: a systematic review and meta-analysis. Br J Clin Pharmacol (2014) 0.88
The antithrombotic profile of aspirin. Aspirin resistance, or simply failure? Thromb J (2004) 0.87
Biological basis and clinical implications of acetylsalicylic acid resistance. Can J Cardiol (2006) 0.87
Antiplatelet therapy in populations at high risk of atherothrombosis. J Natl Med Assoc (2006) 0.84
Native platelet aggregation and response to aspirin in persons with the metabolic syndrome and its components. Metab Syndr Relat Disord (2009) 0.84
The clopidogrel after surgery for coronary artery disease (CASCADE) randomized controlled trial: clopidogrel and aspirin versus aspirin alone after coronary bypass surgery [NCT00228423]. Curr Control Trials Cardiovasc Med (2005) 0.84
Aspirin and clopidogrel response variability: review of the published literature. Tex Heart Inst J (2008) 0.84
Antiplatelet Activity of Morus alba Leaves Extract, Mediated via Inhibiting Granule Secretion and Blocking the Phosphorylation of Extracellular-Signal-Regulated Kinase and Akt. Evid Based Complement Alternat Med (2014) 0.84
Aspirin resistance. BMJ (2004) 0.84
The platelet fibrinogen receptor: from megakaryocyte to the mortuary. JRSM Cardiovasc Dis (2012) 0.83
Effects of cilostazol on platelet activation in coronary stenting patients who already treated with aspirin and clopidogrel. Korean J Intern Med (2004) 0.83
Aspirin resistance in children with heart disease at risk for thromboembolism: prevalence and possible mechanisms. Pediatr Cardiol (2007) 0.83
The inhibitory mechanism of crude saponin fraction from Korean Red Ginseng in collagen-induced platelet aggregation. J Ginseng Res (2015) 0.82
Tocotrienols-induced inhibition of platelet thrombus formation and platelet aggregation in stenosed canine coronary arteries. Lipids Health Dis (2011) 0.82
Oncocalyxone A inhibits human platelet aggregation by increasing cGMP and by binding to GP Ibalpha glycoprotein. Br J Pharmacol (2008) 0.82
Pharmacogenomics of anti-platelet and anti-coagulation therapy. Curr Cardiol Rep (2013) 0.81
Stent thrombosis in real-world patients: a comparison of drug-eluting with bare metal stents. Neth Heart J (2007) 0.81
Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients. J Vasc Surg (2011) 0.81
Residual platelet ADP reactivity after clopidogrel treatment is dependent on activation of both the unblocked P2Y(1) and the P2Y (12) receptor and is correlated with protein expression of P2Y (12). Purinergic Signal (2006) 0.81
Aspirin resistance in patients with acute ischemic stroke. J Neurol (2011) 0.81
The effect of acetylsalicylic acid resistance on prognosis of patients who have developed acute coronary syndrome during acetylsalicylic acid therapy. Can J Cardiol (2007) 0.81
Antiplatelet drugs: mechanisms and risks of bleeding following cardiac operations. Int J Angiol (2011) 0.80
Hostility and platelet reactivity in individuals without a history of cardiovascular disease events. Psychosom Med (2009) 0.80
Use of native or platelet count adjusted platelet rich plasma for platelet aggregation measurements. J Clin Pathol (2005) 0.80
Current status of antiplatelet agents to prevent stroke. Curr Neurol Neurosci Rep (2011) 0.79
Antiplatelet therapy for carotid artery stenting. Interv Neurol (2013) 0.79
Bleeding tendency in dual antiplatelet therapy with aspirin/clopidogrel: rescue of the template bleeding time in a single-center prospective study. Thromb J (2012) 0.79
Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations. Br J Clin Pharmacol (2011) 0.79
Leukocyte count is associated with increased platelet reactivity and diminished response to aspirin in healthy individuals with a family history of coronary artery disease. Thromb Res (2009) 0.79
Methodological issues and recommendations for systematic reviews of prognostic studies: an example from cardiovascular disease. Syst Rev (2014) 0.79
Emerging therapies for acute coronary syndromes. Front Pharmacol (2011) 0.78
Antiplatelet resistance and the role of associated variables in stable patients treated with stenting. Postepy Kardiol Interwencyjnej (2015) 0.78
Aspirin resistance and other aspirin-related concerns. Neurol Sci (2015) 0.78
Comparison of Aggregometry with Flow Cytometry for the Assessment of Agonists´-Induced Platelet Reactivity in Patients on Dual Antiplatelet Therapy. PLoS One (2015) 0.78
Aspirin treatment failure and the risk of recurrent stroke and death among patients with ischemic stroke. J Stroke Cerebrovasc Dis (2011) 0.78
Abundance- and Activity-Based Proteomics in Platelet Biology. Curr Proteomics (2011) 0.78
Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease. Heart (2008) 0.78
Antiplatelet Resistance-Does it Exist and How to Measure it? Clin Med Cardiol (2009) 0.78
Selective and rapid monitoring of dual platelet inhibition by aspirin and P2Y12 antagonists by using multiple electrode aggregometry. Thromb J (2010) 0.77
High prevalence of aspirin resistance in elderly patients with cardiovascular disease and metabolic syndrome. J Geriatr Cardiol (2016) 0.77
P2RY1 and P2RY12 polymorphisms and on-aspirin platelet reactivity in patients with coronary artery disease. Int J Lab Hematol (2012) 0.77
Oxylipid Profile of Low-Dose Aspirin Exposure: A Pharmacometabolomics Study. J Am Heart Assoc (2015) 0.77
Chinese herbal medicine for aspirin resistance: a systematic review of randomized controlled trials. Evid Based Complement Alternat Med (2014) 0.77
Aspirin resistance and promoting blood circulation and removing blood stasis: current situation and prospectives. Evid Based Complement Alternat Med (2014) 0.77
Boosting platelet inhibition in poor responder to aspirin and clopidogrel undergoing percutaneous coronary intervention: role of tirofiban. J Blood Med (2010) 0.77
Simultaneous angiographic late stent thrombosis in two different coronary vessels after withdrawal of the combined anti-platelet therapy. Clin Res Cardiol (2006) 0.77
Acetylsalicylic acid resistance and clinical outcome--the Hobikoglu study is worth noting. Can J Cardiol (2007) 0.76
Acetylsalicylic Acid resistance in patients with type 2 diabetes mellitus, prediabetes & non-diabetic coronary artery disease. Pak J Med Sci (2014) 0.76
Aspirin resistance: Fact or fiction? A point of view. World J Cardiol (2010) 0.76
The variability of platelet response to aspirin and clopidogrel: revisiting the Caprie, Cure, Credo, and Match trials. Proc (Bayl Univ Med Cent) (2005) 0.76
Combined aspirin and clopidogrel resistance associated with recurrent coronary stent thrombosis. Clin Res Cardiol (2006) 0.76
Establishing a predictive model for aspirin resistance in elderly Chinese patients with chronic cardiovascular disease. J Geriatr Cardiol (2016) 0.75
Preoperative aspirin resistance does not increase myocardial injury during off-pump coronary artery bypass surgery. J Korean Med Sci (2011) 0.75
Aspirin resistance in coronary heart disease: Current understandings and strategies. J Transl Int Med (2016) 0.75
Biochemical aspirin resistance in stroke patients - a cross-sectional single centre study. EXCLI J (2013) 0.75
Aspirin resistance with genetic dyslipidemia: contribution of vascular thromboxane generation. Physiol Genomics (2010) 0.75
Aspirin resistance and its implications in clinical practice. MedGenMed (2005) 0.75
Aspirin therapy for inhibition of platelet reactivity in the presence of erythrocytes in patients with vascular disease. J Lab Clin Med (2006) 0.75
Platelet Function Testing-Guided Antiplatelet Therapy. EJIFCC (2013) 0.75
Aspirin "allergy" and resistance. J Am Coll Cardiol (2004) 0.75
Antiplatelet Effect of Sequential Administration of Cilostazol in Patients with Acetylsalycilic Acid Resistance. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2016) 0.75
Recovery time of platelet function after aspirin withdrawal. Curr Ther Res Clin Exp (2014) 0.75
Towards personalized medicine based on platelet function testing for stent thrombosis patients. Thrombosis (2012) 0.75
Attending to links in the safety chain for drug-eluting stents. Neth Heart J (2006) 0.75
Aspirin prophylaxis for the prevention of thrombosis: expectations and limitations. Thrombosis (2012) 0.75
Aspirin Resistance Predicts Adverse Cardiovascular Events in Patients with Symptomatic Peripheral Artery Disease. Tex Heart Inst J (2016) 0.75
Impact of aspirin and clopidogrel interruption on platelet function in patients undergoing major vascular surgery. PLoS One (2014) 0.75
Overcoming aspirin resistance with loading clopidogrel earlier in elective percutaneous coronary intervention. Int J Angiol (2015) 0.75
Aspirin and clopidogrel resistance using the cone and plate(let) analyser in Indian patients with coronary artery disease. Heart Asia (2014) 0.75
Biomarkers and Bioassays for Cardiovascular Diseases: Present and Future. Biomark Insights (2008) 0.75
Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patients. Braz J Med Biol Res (2017) 0.75
Effect of Oral Anti-platelet Regimens on Platelet Aggregation using Chronolog Light Transmittance Aggregometry in Coronary Heart Disease Patients: An Observational Study. J Clin Diagn Res (2013) 0.75
Therapeutic failure or resistance to aspirin. J Am Coll Cardiol (2004) 0.75
Determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol (2003) 0.75
Aspirin resistance: A fact or a myth? Exp Clin Cardiol (2005) 0.75
6(th) Asian PAD Workshop. Ann Vasc Dis (2015) 0.75
[Primary prevention of coronary heart disease with aspirin]. Z Kardiol (2005) 0.75
Monitoring aspirin therapy in children after interventional cardiac catheterization: laboratory measures, dose response, and clinical outcomes. Eur J Pediatr (2015) 0.75
Point-of-Care-Testing in Acute Stroke Management: An Unmet Need Ripe for Technological Harvest. Biosensors (Basel) (2017) 0.75
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Assessing the impact of population stratification on genetic association studies. Nat Genet (2004) 16.28
Human genetic variation and its contribution to complex traits. Nat Rev Genet (2009) 12.11
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA (2002) 11.06
Evaluation of next generation sequencing platforms for population targeted sequencing studies. Genome Biol (2009) 9.59
Effect of direct-to-consumer genomewide profiling to assess disease risk. N Engl J Med (2011) 6.90
Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet (2003) 6.85
Common vs. rare allele hypotheses for complex diseases. Curr Opin Genet Dev (2009) 6.85
Prevalence of conventional risk factors in patients with coronary heart disease. JAMA (2003) 6.84
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA (2011) 6.39
9p21 DNA variants associated with coronary artery disease impair interferon-γ signalling response. Nature (2011) 6.25
Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med (2003) 5.89
Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet (2003) 5.34
The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet (2004) 5.31
Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA (2004) 5.11
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet (2002) 5.04
Microdroplet-based PCR enrichment for large-scale targeted sequencing. Nat Biotechnol (2009) 4.80
Can mobile health technologies transform health care? JAMA (2013) 4.75
Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med (2003) 4.72
A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet (2005) 4.45
Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med (2007) 4.30
Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA (2005) 4.23
Pathway analysis of seven common diseases assessed by genome-wide association. Genomics (2008) 4.11
Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet (2010) 3.97
Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA (2008) 3.64
Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation (2003) 3.38
Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science (2003) 3.34
Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. Ann Intern Med (2010) 3.17
Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol (2005) 3.05
Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. N Engl J Med (2002) 3.01
Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. J Am Coll Cardiol (2004) 2.97
Characterization of circulating endothelial cells in acute myocardial infarction. Sci Transl Med (2012) 2.91
Arthritis medicines and cardiovascular events--"house of coxibs". JAMA (2004) 2.89
Accurate detection and genotyping of SNPs utilizing population sequencing data. Genome Res (2010) 2.84
Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J (2005) 2.80
Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med (2008) 2.61
Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol (2005) 2.59
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol (2007) 2.56
Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features. Circulation (2004) 2.54
Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet (2012) 2.53
Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trial. J Am Coll Cardiol (2007) 2.47
International differences in evolution of early discharge after acute myocardial infarction. Lancet (2004) 2.47
A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol (2007) 2.47
The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? Per Med (2011) 2.43
Premature myocardial infarction novel susceptibility locus on chromosome 1P34-36 identified by genomewide linkage analysis. Am J Hum Genet (2004) 2.36
Enrichment of sequencing targets from the human genome by solution hybridization. Genome Biol (2009) 2.32
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J (2007) 2.31
Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA (2005) 2.26
The importance of phase information for human genomics. Nat Rev Genet (2011) 2.25
Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke (2004) 2.24
Consumer perceptions of direct-to-consumer personalized genomic risk assessments. Genet Med (2010) 2.23
The case for routine genotyping in dual-antiplatelet therapy. J Am Coll Cardiol (2010) 2.19
Sex differences in mortality following acute coronary syndromes. JAMA (2009) 2.17
Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET). J Am Coll Cardiol (2003) 2.17
Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. Am J Hum Genet (2010) 2.15
Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov (2003) 2.06
Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation (2008) 2.05
The genetics of health. Nat Genet (2006) 2.04
Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs. Am J Med (2006) 2.02
Towards precise classification of cancers based on robust gene functional expression profiles. BMC Bioinformatics (2005) 2.01
The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc (2005) 2.00
A covering method for detecting genetic associations between rare variants and common phenotypes. PLoS Comput Biol (2010) 1.98
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet (2012) 1.96
Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA (2005) 1.94
Identification of four gene variants associated with myocardial infarction. Am J Hum Genet (2005) 1.89
Impact of direct-to-consumer genomic testing at long term follow-up. J Med Genet (2013) 1.86
A common MECP2 haplotype associates with reduced cortical surface area in humans in two independent populations. Proc Natl Acad Sci U S A (2009) 1.84
Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J (2009) 1.80
Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation (2009) 1.77
Longitudinal genome-wide association of cardiovascular disease risk factors in the Bogalusa heart study. PLoS Genet (2010) 1.76
Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med (2009) 1.76
Molecular regulation of contractile smooth muscle cell phenotype: implications for vascular tissue engineering. Tissue Eng Part B Rev (2010) 1.76
Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. J Am Coll Cardiol (2003) 1.75
Cardiology and emergency medicine: united we stand, divided we fall. Ann Emerg Med (2002) 1.72
Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword? Circulation (2002) 1.70
A 16-week randomized clinical trial of 2000 international units daily vitamin D3 supplementation in black youth: 25-hydroxyvitamin D, adiposity, and arterial stiffness. J Clin Endocrinol Metab (2010) 1.69
Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol (2007) 1.66
Transcription factor MEF2A mutations in patients with coronary artery disease. Hum Mol Genet (2004) 1.65
Impact of blood transfusion on short- and long-term mortality in patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv (2009) 1.64
Direct-to-consumer personalized genomic testing. Hum Mol Genet (2011) 1.61
Direct-to-consumer pharmacogenomic testing is associated with increased physician utilisation. J Med Genet (2013) 1.61
Comparison of outcomes of patients with myocardial infarction when living alone versus those not living alone. Am J Cardiol (2002) 1.60
Gene variants of VAMP8 and HNRPUL1 are associated with early-onset myocardial infarction. Arterioscler Thromb Vasc Biol (2006) 1.60
Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med (2003) 1.59
Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial. Am J Cardiol (2007) 1.59
Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. Am Heart J (2004) 1.58
Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation (2002) 1.58
Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation (2003) 1.55
Predictors of revascularization method and long-term outcome of percutaneous coronary intervention or repeat coronary bypass surgery in patients with multivessel coronary disease and previous coronary bypass surgery. Eur Heart J (2005) 1.54
Granulocyte colony stimulating factor in patients with large acute myocardial infarction: results of a pilot dose-escalation randomized trial. Am Heart J (2006) 1.53
Blockade of the platelet P2Y12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model. Arterioscler Thromb Vasc Biol (2003) 1.52
Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity. JACC Cardiovasc Interv (2010) 1.51